A Phase 1 interventional study of Alisertib in Advanced Solid Tumors and Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.
Among the 26 studies in Lymphoma by Takeda, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 1, and was the 12th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 36 across the 23 interventional studies, 1,000 across the 3 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Lymphoma by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.
The drug being tested in this study is called alisertib. Alisertib is being tested in adult participants with advanced solid tumors or lymphomas.
The study enrolled 26 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one alisertib tablet (ECT), orally, with or without a standard high-fat breakfast Cycle 1, Day 1, with the respective alternate food intake condition (fasted to fed or fed to fasted) on Cycle 2, Day 1, each followed by 14-day rest period. Participants will take alisertib, ECT, orally BID on Days 4 to 10 of Cycles 1 and 2, each followed by 14-day rest period. From Cycle 3 onwards participants will continue taking alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity.
This multi-center trial conducted at 3 sites in the United States. Participants will make multiple visits to the clinic and plus a final visit after 30 days of receiving their last dose of drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
Drug: Alisertib
Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
Drug: Alisertib
Alisertib ECT
Also known as: MLN8237
Cmax: Maximum Observed Plasma Concentration of Alisertib
Time frame: Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib
Time frame: Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib
Time frame: Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From first dose through 30 days after the last dose of study drug (up to 225 days)
Number of Participants With Clinically Significant Change in Laboratory Parameters Reported as AEs
The number of participants with any clinical significant change in safety laboratory values collected throughout the study.
Time frame: From first dose through 30 days after the last dose of study drug (up to 225 days)
Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs
The number of participants with any clinical significant change in vital signs (sitting diastolic and systolic blood pressure, heart rate, and temperature) were collected throughout the study.
Time frame: From first dose through 30 days after the last dose of study drug (up to 225 days)
Participants took part in the study at 3 investigative sites in the United States from 16 July 2013 to 24 January 2017. Data cut-off for the primary analysis was 05 March 2014.
| Milestone | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed |
|---|---|---|
| Started | 13 | 13 |
| Completed | 7 | 5 |
| Not completed | 6 | 8 |
| Withdrew: Progressive disease | 1 | 5 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Symptomatic deterioration | 2 | 0 |
| Withdrew: Reason not specified | 0 | 1 |
| nM | Alisertib 50 mg Fed | Alisertib 50 mg Fasted |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration of Alisertib | 1338.6 ± 487.25 | 1354.5 ± 432.17 |
| hr*nM | Alisertib 50 mg Fed | Alisertib 50 mg Fasted |
|---|---|---|
| AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib | 24645.5 ± 12467.39 | 20797.7 ± 8847.69 |
| hr*nM | Alisertib 50 mg Fed | Alisertib 50 mg Fasted |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib | 24537.5 ± 9882.10 | 22771.4 ± 10206.21 |
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| Participants | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed |
|---|---|---|
| AEs | 13 | 13 |
| SAEs | 7 | 7 |
The number of participants with any clinical significant change in safety laboratory values collected throughout the study.
| Participants | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed |
|---|---|---|
| Neutropenia | 10 | 8 |
| Anaemia | 5 | 3 |
| Leukopenia | 5 | 2 |
| Thrombocytopenia | 1 | 2 |
| Hypokalaemia | 0 | 3 |
| Hyperbilirubinaemia | 1 | 1 |
| Neutrophil count decreased | 1 | 1 |
| Lymphopenia | 0 | 1 |
| Hyperkalaemia | 1 | 0 |
| Hypomagnesaemia | 0 | 1 |
| Aspartate aminotransferase increased | 0 | 1 |
| Blood bilirubin increased | 1 | 0 |
The number of participants with any clinical significant change in vital signs (sitting diastolic and systolic blood pressure, heart rate, and temperature) were collected throughout the study.
| Participants | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed |
|---|---|---|
| Hypertension | 0 | 1 |
| Hypotension | 0 | 1 |
| Tachycardia | 0 | 1 |
Collected over From first dose through 30 days after the last dose of study drug (up to 225 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib 50 mg Fed + Fasted | 0/13 (0%) | 7/13 (53.8%) | 13/13 (100%) |
| Alisertib 50 mg Fasted + Fed | 1/13 (7.7%) | 7/13 (53.8%) | 13/13 (100%) |
| Event | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed |
|---|---|---|
| Abdominal painGastrointestinal disorders | 2/13 | 1/13 |
| Rectal haemorrhageGastrointestinal disorders | 0/13 | 1/13 |
| CellulitisInfections and infestations | 0/13 | 1/13 |
| BacteraemiaInfections and infestations | 1/13 | 0/13 |
| Pneumonia streptococcalInfections and infestations | 1/13 | 0/13 |
| PyelonephritisInfections and infestations | 0/13 | 1/13 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/13 | 0/13 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/13 | 1/13 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/13 | 1/13 |
| DeliriumPsychiatric disorders | 0/13 | 1/13 |
| Event | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 11/13 | 8/13 |
| FatigueGeneral disorders | 8/13 | 3/13 |
| StomatitisGastrointestinal disorders | 3/13 | 8/13 |
| AlopeciaSkin and subcutaneous tissue disorders | 8/13 | 7/13 |
| VomitingGastrointestinal disorders | 3/13 | 7/13 |
| AnaemiaBlood and lymphatic system disorders | 6/13 | 4/13 |
| LeukopeniaBlood and lymphatic system disorders | 5/13 | 3/13 |
| PyrexiaGeneral disorders | 1/13 | 5/13 |
| DiarrhoeaGastrointestinal disorders | 5/13 | 4/13 |
| NauseaGastrointestinal disorders | 2/13 | 5/13 |
Safety population included all enrolled participants who received at least one dose of study drug.
| Age, Continuous(years) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| Mean | 59.6 ± 10.15 | 61.7 ± 12.64 | 60.7 ± 11.28 |
| Sex: Female, Male(Participants) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 7 | 6 | 13 |
| Race/Ethnicity, Customized(Participants) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 8 | 9 | 17 |
| Race/Ethnicity, Customized(Participants) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| White | 10 | 13 | 23 |
| Black or African American | 3 | 0 | 3 |
| Region of Enrollment(Participants) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| United States | 13 | 13 | 26 |
| Height(cm) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| Mean | 166.9 ± 14.34 | 165.3 ± 11.32 | 166.1 ± 12.68 |
| Weight(kg) | Alisertib 50 mg Fed + Fasted | Alisertib 50 mg Fasted + Fed | Total |
|---|---|---|---|
| Mean | 73.59 ± 15.484 | 78.37 ± 20.183 | 75.98 ± 17.792 |
Ran from Jul 2013 to primary completion in Mar 2014, 7 months.
Results were first posted in Jun 2019, 5 years 3 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 7 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →